Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR) — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
United States
Research Site, Sacramento, California Research Site, Houston, Texas China
Research Site, Shanghai, Shanghai Municipality Last updated September 2024